Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Kansas City, KA
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
New Orleans, LA
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Baltimore, MD
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Boston, MA
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Lansing, MI
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Lansing, MI
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Duluth, MN
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Duluth, MN
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Investigational Site
mi
from
Corinth, MS
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Investigational Site
mi
from
Corinth, MS
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Columbia, MO
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Columbia, MO
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Jefferson City, MO
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Jefferson City, MO
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Omaha, NE
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Las Vegas, NV
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Hackensack, NJ
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
East Syracuse, NY
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
East Syracuse, NY
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
New York, NY
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Durham, NC
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Raleigh, NC
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Kettering, OH
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Kettering, OH
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Tualatin, OR
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Tualatin, OR
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Hershey, PA
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Hershey, PA
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Lancaster, PA
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Lancaster, PA
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
mi
from
Piitsburgh, PA
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
mi
from
Piitsburgh, PA
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Charleston, SC
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Columbia, SC
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Columbia, SC
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Chattanooga, TN
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Nashville, TN
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Amarillo, TX
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Amarillo, TX
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Bedford, TX
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Bedford, TX
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Dallas, TX
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Denton, TX
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Denton, TX
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Tyler, TX
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Norfolk, VA
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  3/4/2016
mi
from
Garran,
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 3/4/2016
mi
from
Garran,
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Nebraska Methodist Hospital
mi
from
Omaha, NE
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Smilow Cancer Hospital Care Center at Saint Francis
mi
from
Hartford, CT
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Smilow Cancer Hospital Care Center at Saint Francis
mi
from
Hartford, CT
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
The Hospital of Central Connecticut
mi
from
New Britain, CT
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
The Hospital of Central Connecticut
mi
from
New Britain, CT
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
MedStar Washington Hospital Center
mi
from
Washington,
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Florida Hospital Orlando
mi
from
Orlando, FL
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Florida Hospital Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Saint Vincent Oncology Center
mi
from
Indianapolis, IN
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Saint Vincent Oncology Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
MedStar Franklin Square Medical Center/Weinberg Cancer Institute
mi
from
Baltimore, MD
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
MedStar Franklin Square Medical Center/Weinberg Cancer Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Saint Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Saint Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Michigan Cancer Research Consortium CCOP
mi
from
Ann Arbor, MI
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Michigan Cancer Research Consortium CCOP
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Oakwood Hospital and Medical Center
mi
from
Dearborn, MI
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Oakwood Hospital and Medical Center
mi
from
Dearborn, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Saint John Hospital and Medical Center
mi
from
Detroit, MI
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Saint John Hospital and Medical Center
mi
from
Detroit, MI
Click here to add this to my saved trials